Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
0.5 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Knowledge Ecology International Europe (KEI Europe)
EU Transparency Register
274093330410-67 First registered on 26 Feb 2018
Goals / Remit
Knowledge Ecology International Europe (KEI Europe) is a non-profit organization focusing on the management of knowledge, including innovation and access to knowledge goods.
KEI Europe is a not-for-profit Swiss association with offices in Geneva, Switzerland.
KEI Europe monitors Brussels and Geneva-based trade, health and IPR negotiations, KEI Europe has extensive contacts within governments, academics, consumers organizations and other stakeholders.
As part of its work, KEI Europe endeavors to ensure policy coherence across between positions adopted by the European Union in Brussels with their engagement with global institutions, such as the WHO, WIPO and WTOMain EU files targeted
http://keieurope.org/actions.html
On 31 July 2023, KEI Europe submitted comments on the European Commission’s proposal for a regulation on compulsory licensing.
On 6 June 2023, KEI Europe participated in a meeting convened by the EU delegation in Geneva to discuss the EU’s proposals for the Pandemic Agreement,
On 29 September 2022, KEI Europe contributed to the public consultation on the proposed European Union compulsory licensing framework.
On 29 April 2022, Knowledge Ecology International Europe (KEI Europe) made the following submission on the European Union’s revised framework for compulsory licensing of patents: https://keieurope.org/2022/04/29/kei-europe-submission-on-eu-revised-framework-for-compulsory-licensing-of-patents/
On 30 March 2022, 42 global and European civil society organizations (including KEI Europe) wrote an open letter calling on the European Union to “refrain from rushing WTO members to rapidly adopt a purported proposal on intellectual property rights and COVID-19.”
On 24 February 2021, KEI Europe submitted comments on the European Health Emergency Preparedness and Response Authority (HERA) roadmap
On 14 August 2020, KEI Europe submitted comments on the Intellectual Property Action Plan
On 7 July 2020, KEI Europe submitted comments on the pharmaceutical strategy roadmap.
On 3 March 2020, KEI Europe submitted comments on the cancer roadmap.
In recent years, KEI Europe has advanced a positive agenda in the Transatlantic Trade and Investment (TTIP) negotiations, submitted a detailed proposal to the Government of the United Kingdom requesting the government to issue a compulsory licence on the costly breast cancer treatment, T-DM1, and engaged in media advocacy with the Franco-German television network, ARTE, on the subject of donor capture of the World Health Organization (WHO).
Horizon 2020
2 February 2017. KEI Europe, along with a coalition of groups, called upon the European Commission to reframe Horizon 2020 to explore alternative models of innovation that delinked the cost of R&D from the price of medicines.
January 2017. The joint submission to the Horizon 2020 consultation established six key recommendations that the European Commission should consider during their review process, including increased public investment in biomedical R&D funding, mandates on open data, and increased transparency.
Transatlantic Trade and Investment Partnership Agreement
24 February 2016. KEI Europe delivered an intervention before EU and US TTIP negotiators as well as stakeholders during the 12th round of negotiations in Brussels.
15 July 2015. KEI Europe presented an intervention on issues related to intellectual property and public health at the TTIP stakeholder event during the negotiations in Brussels.
13 July 2014. KEI Europe Submission: European Commission's Public consultation on modalities for investment protection and ISDS in TTIP.Address
Head Office
Route de Morillons 1
Geneva 1211 - CP 2100
SWITZERLANDEU Office
Route de Morillons 1
Geneva 1211 - CP 2100
SWITZERLANDWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 50% 1 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
Trans Atlantic Consumer Dialogue - http://tacd.org/
Member organisations
None declared
-
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
91,809€
Major funding types in closed year
Grants
Major contributions in closed year
None declared
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
http://keieurope.org/actions.html
http://keieurope.org/press/
Some highlights include:
WHO transparency resolution
On 6 March 2019, 83 civil society organizations (including KEI Europe) and 20 individuals wrote an open letter to WHO member states requesting support for Italy’s resolution on “Improving the transparency of markets for drugs, vaccines and other health-related technologies”. The text of the transparency resolution can be found here. Currently, Greece, Malaysia, and Slovenia are co-sponsors of the Italian transparency resolution.
Third Country Report on the protection and enforcement of intellectual property rights in third countries
On 16 April 2018, KEI Europe and 32 groups wrote a letter to the European Commission’s Trade Commissioner, Cecilia Malmström, expressing concerns over the Commission’s
Third Country Report on the protection and enforcement of intellectual property rights in third countries and plans to create an EU Watch List. The text of the letter can be found here: http://keieurope.org/wp-content/uploads/2018/04/Open-Letter-to-Commissioner-Malmström_-EU-Watch-List-2.pdf
The Commission response can be found here: http://keieurope.org/2018/05/17/the-european-commission-response-to-civil-society-concerns-over-the-third-country-report-on-the-protection-of-iprs/
Romania: Hepatitis C (HCV)
KEI Europe has advanced its efforts on compulsory licensing of medical technologies in order to increase access to several drugs in a variety of markets globally. KEI has taken active steps towards increasing access to new, highly effective hepatitis C virus (HCV) treatments in Europe, beginning with Romania. KEI Europe’s endeavors in Romania in relation to the compulsory licensing of HCV treatments was featured in a Politico Europe article published on 16 March 2016 (Skyhigh drug prices made Romania mull unusual path, http://www.politico.eu/pro/high-drug-prices-romania-changes-patents-hepatitis).
United Kingdom: T-DM1
Between 2016 and 2017, KEI Europe spearheaded the Coalition for Affordable T-DM1’s campaign in the United Kingdom of Great Britain and Northern Ireland (UK) requesting the UK government to authorize the domestic manufacture and/or importation, use and sale of biosimilar versions of trastuzumab emtansine (T-DM1) used in the treatment of breast cancer, to be supplied to the government for use and sale in the UK. This followed on from the Coalition for Affordable T-DM1’s October 2015 notice of intent requesting for the government to exercise Crown Use provisions on the patents on T-DM1. To see the October 2015 notice of intent in full, please see: (http://keieurope.org/files/JeremyHuntIntenttoRequest1October2015.pdf). To see the full detailed submission, see: http://keieurope.org/files/JeremyHunt25November2016CompulsoryLicenceRequest.pdf
World Health Organization
30 March 2017. KEI Europe, in conjunction with sixteen other civil society groups, submitted a letter to the EU urging they voice support for a resolution on a feasibility study concerning delinkage models for cancer treatment R&D at the upcoming 70th World Health Assembly.
WTO Agreement on the Supply of Public Goods
27-29 March 2015. KEI Europe convened an expert meeting to consider a text for a World Trade Organization (WTO) Agreement for the Supply of Social/Public Goods (SGA Agreement). The meeting was held in Berlin, Germany and served as a space for experts with backgrounds in international trade, law, the environment, development, public health and open collaborative development models to review draft articles of the proposed agreement on social goods and provide technical and strategic advice. The report of the meeting can be found here:
https://www.boell.de/sites/default/files/final_report_wtoagreementpublicgoods.pdfOther activities
None declared
- Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 15 May 2018 Location Brussels Subject Access to medicines in poor countries Cabinet Cabinet of Vice-President Cecilia Malmström Portfolio Trade Attending - Pedro Velasco Martins (Cabinet member)
- Maria Asenius (Cabinet member)
Other Lobbyists
- Meetings